Aviir (Irvine, CA) a commercial-stage diagnostic company focused on pharmacogenomic and genetic tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders, closed a $10M Series E financing. Participants include Merck Global Health Innovation, Bay City Capital, Aberdare Ventures and New Leaf Venture Partners.
Nevro (Menlo Park, CA) a clinical-stage medical device company focused on neuromodulation for the relief of chronic pain, closed a $58M Series B financing. Participants include Johnson & Johnson Development Corp, Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, MPM Capital and Three Arch Partners.
Conatus Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on hepatic disease and oncology, closed a $20M Series B financing. Participants include AgeChem Venture Fund, Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners and Roche Venture Fund.
NextWave Pharmaceuticals (Cupertino, CA) a clinical-stage specialty pharmaceutical focused on cardiovascular and CNS diseases, closed a $45M Series C financing. Participants include Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures.
Merus (Netherlands) a preclinical-stage biopharmaceutical focused on antibody product candidates against targets in oncology, inflammation and infectious disease, closed a $30.7M Series B financing. Participants include Novartis Option Fund, Pfizer, Bay City Capital, Life Sciences Partners and Aglaia Biomedical Ventures.
Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers. Note: 2009 Year-in-Review Trend Analysis Coming 15 [...]
Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications. Participants include Bay City Capital, Amgen Ventures, Astellas Venture Management, MPM Capital and Kleiner Perkins Caufield and Byers. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.